What are the indications for aspirin desensitization therapy?

Indications for Aspirin Desensitization Therapy

Aspirin desensitization is primarily indicated for two clinical scenarios: (1) patients with aspirin-exacerbated respiratory disease (AERD) who have inadequately controlled upper or lower respiratory symptoms despite optimal medical therapy, and (2) patients with coronary artery disease requiring aspirin for secondary prevention who have a documented history of aspirin hypersensitivity. 1

Primary Indication: Aspirin-Exacerbated Respiratory Disease (AERD)

Clinical Criteria for AERD Desensitization

Aspirin desensitization should be pursued in AERD patients when:

• Persistent symptoms despite aggressive medical management including inhaled corticosteroids and leukotriene-modifying agents 1
• Recurrent nasal polyps requiring multiple revision polypectomies 2, 3
• Need for systemic corticosteroids to control nasal symptoms or asthma 4
• Suboptimally controlled asthma or rhinosinusitis despite standard therapy 5

The evidence demonstrates that aspirin desensitization improves clinical outcomes for both upper and lower respiratory tract disease in AERD, with cost-effectiveness data showing $6,768 per quality-adjusted life-year 1. This represents a therapeutic intervention, not just tolerance induction—patients maintain daily aspirin therapy (typically 650 mg twice daily after desensitization) to achieve disease control 1.

AERD Patient Characteristics

AERD is defined by the clinical triad of:

• Chronic rhinosinusitis with nasal polyps
• Asthma
• Intolerance to COX-1 inhibiting medications 2

Most patients react at aspirin doses between 40.25 mg and 120 mg during desensitization 1.

Secondary Indication: Cardiovascular Disease

Acute Coronary Syndrome or Coronary Stent Placement

For patients with acute coronary syndromes or requiring percutaneous coronary intervention who have a history of aspirin hypersensitivity, aspirin desensitization (or preferably, graded challenge) is indicated 1.

Important distinction: In patients with remote history of NSAID reaction and no AERD or active urticaria, a graded challenge is preferred over desensitization because:

• It provides a definitive diagnosis (85% of challenges are negative) 1
• It's simpler and faster
• It avoids perpetuating an incorrect "aspirin allergy" label
• Large series show safety with only 3 of 262 challenges requiring epinephrine, with no hemodynamic instability 1

The multicenter ADAPTED registry demonstrated 95.4% success rate with rapid desensitization protocols across all types of aspirin sensitivity manifestations (urticaria, angioedema, asthma, anaphylaxis) in patients undergoing coronary angiography 6.

When to Choose Desensitization vs. Challenge in Cardiovascular Patients

Choose graded challenge when:

• Remote history of NSAID reaction
• No features of AERD
• No active urticaria
• Hemodynamically stable 1

Choose desensitization when:

• History consistent with AERD (respiratory reactions, nasal polyposis, asthma)
• Extremely unstable patients requiring lower starting doses
• Active NSAID-exacerbated cutaneous disease (though this may result in persistent urticaria) 1

Contraindications and Precautions

Absolute Contraindications

• Active gastrointestinal bleeding
• Severe uncontrolled asthma (FEV1 <70% predicted is a relative contraindication)
• Recent major surgery where bleeding risk is prohibitive

Pre-Desensitization Optimization

Mandatory pretreatment for AERD patients:

• Leukotriene-modifying agents to diminish lower respiratory asthmatic response (if not already taking) 1
• Inhaled corticosteroid/long-acting beta agonist to optimize asthma control and diminish NSAID-induced bronchospasm 1

Maintenance Requirements

Critical caveat: Tolerance is lost if aspirin is discontinued:

• >48 hours off aspirin: May lose tolerance 1
• >5 days off aspirin: All patients will react and require repeat desensitization 1

For surgical procedures:

• If surgery can be performed within 48-hour window, restart aspirin immediately postoperatively at previous dose 1
• Alternative: Reduce to 325 mg daily for 7 days pre-surgery, hold day before and day of surgery, restart immediately postoperatively 1
• Consider ibuprofen bridging to reduce bleeding complications 1

Clinical Outcomes

Once desensitized, patients achieve universal tolerance to all COX-1 inhibiting NSAIDs, not just aspirin 1. For AERD patients, maintenance therapy typically requires 650 mg twice daily for optimal control of nasal polyps and airway inflammation, though at least 325 mg daily is needed to maintain tolerance 1.